Status: Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as compared to placebo. The estimated participant overall duration is approximately 15 months.
Participants needed: 510
Trial details
Phase: Phase 3Age: 12+Biological sex: AllType: InterventionalSponsor: Nektar TherapeuticsUpdated: Aug 4, 2026Locations: 12
Eligibility criteria
Male or female patients, ≥ 12 years of age on the day of signing the informed co... [+6]
Are currently experiencing or have a history of concomitant skin conditions othe... [+5]